

Geoffrey R Oxnard

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11493316/geoffrey-r-oxnard-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

138
papers

12,250
citations

49
h-index

110
g-index

157
ext. papers

15,007
ext. citations

9.3
avg, IF

6.27
L-index

#	Paper	IF	Citations
138	Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. <i>Nature Medicine</i> , 2015 , 21, 560-2	50.5	1021
137	Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3375-82	2.2	605
136	Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. <i>Clinical Cancer Research</i> , 2014 , 20, 1698-1705	12.9	580
135	Rociletinib in EGFR-mutated non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 1700-9	59.2	524
134	Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. <i>Clinical Cancer Research</i> , 2011 , 17, 1616-22	12.9	470
133	Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. <i>Clinical Cancer Research</i> , 2011 , 17, 1169-80	12.9	467
132	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1631-1641	2.2	448
131	Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. <i>JAMA Oncology</i> , 2016 , 2, 1014-22	13.4	412
130	MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. <i>Journal of Clinical Oncology</i> , 2016 , 34, 721-30	2.2	383
129	Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. <i>Science Translational Medicine</i> , 2011 , 3, 90ra59	17.5	383
128	Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. <i>JAMA Oncology</i> , 2018 , 4, 1527-1534	13.4	342
127	Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. <i>Clinical Cancer Research</i> , 2011 , 17, 6298-303	12.9	330
126	Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. <i>Science Translational Medicine</i> , 2013 , 5, 216ra177	17.5	313
125	Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. <i>Annals of Oncology</i> , 2020 , 31, 745-759	10.3	303
124	Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. <i>Clinical Cancer Research</i> , 2012 , 18, 1167-76	12.9	297
123	New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 5530-7	12.9	282
122	"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. <i>Neuro-Oncology</i> , 2011 , 13, 1364-9	1	268

121	New targetable oncogenes in non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1097-1042	2.2	249
120	Institutional implementation of clinical tumor profiling on an unselected cancer population. <i>JCI Insight</i> , 2016 , 1, e87062	9.9	245
119	False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. <i>Clinical Cancer Research</i> , 2018 , 24, 4437-4443	14.9	210
118	A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1690-700	8.9	203
117	Efficacy of Selpercatinib in Fusion-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020 , 383, 813-824	59.2	194
116	Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 179-84	8.9	182
115	Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2016 , 22, 915-22	12.9	177
114	Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1726-35	8.9	155
113	Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC. <i>Scientific Reports</i> , 2016 , 6, 33860	4.9	128
112	EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. <i>Clinical Cancer Research</i> , 2012 , 18, 1790-7	12.9	115
111	Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3114-9	2.2	110
110	Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors. <i>Oncologist</i> , 2013 , 18, 1214-20	5.7	108
109	Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016 , 2, 313-20	13.4	106
108	Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 89, 880-7	4	104
107	When progressive disease does not mean treatment failure: reconsidering the criteria for progression. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 1534-41	9.7	96
106	Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer. <i>Cancer Discovery</i> , 2016 , 6, 1334-1341	24.4	94
105	Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2014 , 15, 1433-1441	21.7	92
104	Screening for germline EGFR T790M mutations through lung cancer genotyping. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1049-52	8.9	92

103	A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. <i>Clinical Cancer Research</i> , 2010 , 16, 4647-53	12.9	89
102	A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. <i>Clinical Cancer Research</i> , 2016 , 22, 6010-6020	12.9	84
101	Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. <i>Cancer Research</i> , 2017 , 77, 2712-2721	10.1	81
100	ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 5439-44	12.9	76
99	Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 431-7	8.9	73
98	Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2015 , 21, 2851-60	12.9	72
97	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2018 , 142, 1242-1253	5	72
96	Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation. <i>Clinical Lung Cancer</i> , 2015 , 16, e101-4	4.9	70
95	Application of Plasma Genotyping Technologies in Non-Small Cell Lung Cancer: A Practical Review. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1344-1356	8.9	67
94	Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. <i>Clinical Cancer Research</i> , 2020 , 26, 2615-2625	12.9	60
93	Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. <i>Medical Physics</i> , 2004 , 31, 1105-15	4.4	60
92	Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1901-1911	8.9	59
91	Discrimination of Germline T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. <i>Clinical Cancer Research</i> , 2017 , 23, 7351-7359	12.9	52
90	Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. <i>Lung Cancer</i> , 2006 , 52, 141-8	5.9	50
89	Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer. <i>JAMA Oncology</i> , 2017 , 3, 740-741	13.4	49
88	Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. <i>Journal of Clinical Oncology</i> , 2018 , JCO1800328 ²⁻²		49
87	Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA. <i>Lung Cancer</i> , 2019 , 134, 96-99	5.9	45
86	Clinical Implications of Variant ALK FISH Rearrangement Patterns. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1648-52	8.9	44

85	Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib. <i>Clinical Cancer Research</i> , 2011 , 17, 6322-8	12.9	42
84	The cellular origins of drug resistance in cancer. <i>Nature Medicine</i> , 2016 , 22, 232-4	50.5	40
83	Realizing the potential of plasma genotyping in an age of genotype-directed therapies. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	38
82	Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. <i>Cancer</i> , 2015 , 121, 2570-7	6.4	35
81	Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping. <i>Lung Cancer</i> , 2018 , 122, 72-75	5.9	35
80	Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 56-62	19.4	35
79	Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non-Small-Cell Lung Cancer With Brain Metastases. <i>JAMA Oncology</i> , 2017 , 3, 1274-1275	13.4	34
78	EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1995-2002	8.9	34
77	Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib. <i>Clinical Cancer Research</i> , 2021 , 27, 34-42	12.9	32
76	Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2021 , 71, 176-190	220.7	31
75	EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. <i>Clinical Cancer Research</i> , 2018 , 24, 6548-6555	12.9	31
74	Non-small cell lung cancer in octogenarians: treatment practices and preferences. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 1029-35	8.9	30
73	Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans. <i>Academic Radiology</i> , 2005 , 12, 1301-9	4.3	29
72	Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12003-12003	2.2	29
71	Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. <i>Cancer Research</i> , 2015 , 75, 3139-46	10.1	26
70	Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms. <i>Clinical Cancer Research</i> , 2021 , 27, 3094-3105	12.9	26
69	Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2014 , 120, 2289-98	6.4	25
68	Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors. <i>JAMA Oncology</i> , 2016 , 2, 772-9	13.4	24

67	Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2509-2509	2.2	24
66	Circulating tumor DNA analysis in the era of precision oncology. <i>Oncotarget</i> , 2020 , 11, 188-211	3.3	24
65	Enhanced ratio of signals enables digital mutation scanning for rare allele detection. <i>Journal of Molecular Diagnostics</i> , 2015 , 17, 284-92	5.1	23
64	A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations. <i>Clinical Cancer Research</i> , 2017 , 23, 7467-7473	12.9	22
63	Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations. <i>Cancer Discovery</i> , 2021 , 11, 591-598	24.4	20
62	Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR-mutant lung cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7547-7547	2.2	18
61	Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA. <i>Clinical Cancer Research</i> , 2021 , 27, 4221-4229	12.9	18
60	Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2012 , 136, 1205-9	5	14
59	Precision Medicine in Non-Small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 708-715	7.1	14
58	Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. <i>Oncology</i> , 2010 , 24, 392-9	1.8	13
57	Use of Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 2393-2403	12.9	12
56	Genome-wide cell-free DNA (cfDNA) methylation signatures and effect on tissue of origin (TOO) performance.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3049-3049	2.2	12
55	Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. <i>Lung Cancer</i> , 2020 , 140, 35-41	5.9	12
54	Intracranial Efficacy of Selpercatinib in Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 4160-4167	12.9	12
53	Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development. <i>Cancer</i> , 2016 , 122, 3456-3463	6.4	11
52	The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. <i>Cancers</i> , 2021 , 13,	6.6	11
51	Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 ,	7.1	10
50	Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8015-8015	2.2	10

49	Early Intervention in Lung Cancers With Rapid Plasma Genotyping for EGFR and KRAS Mutations-Reply. <i>JAMA Oncology</i> , 2016 , 2, 1096-7	13.4	10
48	Does TMB Impact the Effectiveness of TKIs in -Mutant NSCLC?. <i>Clinical Cancer Research</i> , 2019 , 25, 899-900.	12.9	10
47	Effective Cancer Genotyping-Many Means to One End. <i>Clinical Cancer Research</i> , 2019 , 25, 4583-4585	12.9	9
46	Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials. <i>Chinese Clinical Oncology</i> , 2015 , 4, 37	2.3	8
45	Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes. <i>Clinical Cancer Research</i> , 2013 , 19, 1634-6	12.9	7
44	Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology. <i>JCO Clinical Cancer Informatics</i> , 2018 , 2, 1-12	5.2	7
43	Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. <i>Molecular Oncology</i> , 2021 , 15, 27-42	7.9	6
42	Traditional Diagnostics versus Disruptive Technology: The Role of the Pathologist in the Era of Liquid Biopsy. <i>Cancer Research</i> , 2020 , 80, 3197-3199	10.1	5
41	Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial. <i>European Radiology</i> , 2021 , 31, 1853-1862	8	5
40	Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	4
39	Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCR. <i>Methods in Molecular Biology</i> , 2018 , 1768, 193-207	1.4	4
38	Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors. <i>Clinical Lung Cancer</i> , 2018 , 19, e655-e665	4.9	4
37	Acquired Resistance to Targeted Therapies in Advanced Non-Small Cell Lung Cancer: New Strategies and New Agents. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , e272-e278	7.1	4
36	The Circulating Cell-free Genome Atlas (CCGA) Study: Follow-up (F/U) on non-cancer participants with cancer-like cell-free DNA signals.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5574-5574	2.2	4
35	Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	4
34	Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis.. <i>JAMA Oncology</i> , 2022 ,	13.4	3
33	Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9048-9048	2.2	3
32	Refining the sensitivity of plasma cell-free DNA (cfDNA) genotyping by controlling for plasma tumor content.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9071-9071	2.2	3

31	Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2021 , 81, 37-37	10.2	3
30	Genomic immunotherapy (IO) biomarkers detected on comprehensive genomic profiling (CGP) of tissue and circulating tumor DNA (ctDNA).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2541-2541	2.2	3
29	Identification of a RAS-activating Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 4072-4079	12.9	2
28	Hereditary Lung Cancer Risk: Recent Discoveries and Implications for Genetic Counseling and Testing. <i>Current Genetic Medicine Reports</i> , 2018 , 6, 83-88	2.2	2
27	The radiologic measurement of mesothelioma. <i>Hematology/Oncology Clinics of North America</i> , 2005 , 19, 1053-66, vi	3.1	2
26	Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation. <i>Clinical Cancer Research</i> , 2020 , 26, 6464-6474 ^{12.9}	12.9	2
25	Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). <i>Immunotherapy</i> , 2021 , 13, 727-734	3.8	2
24	Reply to E.M. Gilles. <i>Journal of Clinical Oncology</i> , 2012 , 30, 117-117	2.2	1
23	An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scans.. <i>European Journal of Cancer</i> , 2022 , 161, 138-147	7.5	1
22	Implementation of clinical next-generation sequencing (NGS) of non-small cell lung cancer (NSCLC) to identify EGFR amplification as a potentially targetable oncogenic alteration.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8090-8090	2.2	1
21	Prediction of lung cancer genotype noninvasively using droplet digital PCR (ddPCR) analysis of cell-free plasma DNA (cfDNA).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8059-8059	2.2	1
20	ERBB2 copy number (CN) as a quantitative biomarker for real-world (RW) outcomes to anti-HER2 therapy in advanced gastroesophageal adenocarcinoma (adv GEA).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4045-4045	2.2	1
19	High Sensitivity of Plasma Cell-Free DNA Genotyping in Cases With Evidence of Adequate Tumor Content. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	1
18	Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 25-25	2.2	1
17	Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program. <i>Oncology and Therapy</i> , 2018 , 6, 45-58	2.7	1
16	Radiologic Assessment of Mesothelioma 2005 , 433-453		1
15	Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.. <i>JAMA Network Open</i> , 2022 , 5, e225394	10.4	1
14	SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100151	1.4	0

13	Savolitinib □ Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: PH1b TATTON Part C. <i>Targeted Oncology</i> , 2021 , 16, 339-355	5	○
12	Real-world (rw) clinical outcomes on alpelisib (ALP) in patients (pts) with breast cancer (BC) and PIK3CA mutations (PIK3CAm).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1068-1068	2.2	○
11	The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100194	1.4	○
10	Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer. <i>Cancer</i> , 2021 , 127, 4557-4564	6.4	○
9	Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of -mutant lung cancer. <i>Science Translational Medicine</i> , 2021 , 13, eabb3738	17.5	○
8	Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus chemotherapy benefit in first-line metastatic urothelial carcinoma: A real-world study.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 547-547	2.2	○
7	Molecular residual disease (MRD) detection with a tissue comprehensive genomic profiling (CGP)-informed personalized monitoring assay: An exploratory analysis of the IMvigor-010 observation arm.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 448-448	2.2	○
6	Detection of EGFR mutations in non-small cell lung cancer by droplet digital PCR.. <i>PLoS ONE</i> , 2022 , 17, e0264201	3.7	○
5	Genomic evolution from hormonal therapies and suitability of prostate cancer diagnostic specimens for metastatic prostate cancer (mPC) genomic stratification.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 143-143	2.2	○
4	Prevalence of UV Mutational Signatures Among Cutaneous Primary Tumors.. <i>JAMA Network Open</i> , 2022 , 5, e223833	10.4	○
3	Commentary. <i>Clinical Chemistry</i> , 2015 , 61, 586-7	5.5	
2	Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline T790M Mutation. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100146	1.4	
1	Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus taxane chemotherapy benefit in metastatic castration-resistant prostate cancer: A real-world biomarker study.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 162-162	2.2	